RESPIRATORY SYNCYTIAL VIRUS (RSV)

This study tests an RSV vaccine in adults aged 18-59 who have health conditions like chronic lung, heart, or kidney disease that put them at higher risk for severe RSV. The goal is to see if the vaccine triggers a strong immune response and is safe. Participants receive one shot …

This early-stage trial is testing several new vaccine formulas against RSV and H5N1 bird flu in 570 healthy adults aged 18 to 49. The main goals are to check safety and see how well the vaccines trigger an immune response. Participants will receive one or two shots and be followe…

This study looks at how well the RSV vaccine Arexvy works in 170 adults with weakened immune systems. Participants will receive up to 3 vaccine doses over a year and be monitored for side effects and immune response. The goal is to find the best dosing schedule to protect this hi…

This Phase 3 trial is testing a new RSV vaccine in 25,000 adults aged 60 and older. The goal is to see if a single shot can prevent lower respiratory tract disease caused by RSV. Participants are randomly assigned to receive either the vaccine or a placebo, and researchers will m…

This study tests the safety of palivizumab, a drug given as monthly injections, in infants under 24 months who are at high risk for severe RSV disease. About 138 children born prematurely or with certain lung or heart conditions will receive up to 5 doses. Researchers will monito…

This early-stage trial is testing an experimental drug called SIBP-A16 in 140 healthy adults aged 18 to 45. The goal is to see if it is safe and how the body handles it. Participants receive a single injection of the drug, a placebo, or an existing RSV antibody. The study does no…

This study will test 10,000 people in Cambodia for 57 different infectious diseases, including dengue, flu, and malaria. Researchers want to understand how these diseases spread and who is at risk. The goal is to give local health authorities the information they need to create b…